An overview of potassium channel activators for the treatment of overactive bladder: A survey of new structures 2000-2005

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 5, 2006, Pages 573-585

  Argentieri, Thomas M ^a   Butera, John A ^a  

^a PFIZER INC   (United States)

Author keywords

Bladder; IK; KATP; KCNQ; Maxi K; Potassium channel; SK

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; 3 (2,4 DICHLORO 6 METHYLBENZYLAMINO) 4 (1,1 DIMETHYLPROPYLAMINO) 3 CYCLOBUTENE 1,2 DIONE; 3,4 DIAMINOPYRAZOLE DERIVATIVE; 9 (3 CYANOPHENYL) 3,4,6,7,9,10 HEXAHYDRO 1,8(2H,5H) ACRIDINEDIONE; A 151892; A 278637; ANTHRANILIC ACID DERIVATIVE; APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CELECOXIB; DIHYDROPYRIDINE DERIVATIVE; FELODIPINE; GLIBENCLAMIDE; ION TRANSPORT AFFECTING AGENT; ISOXAZOLE DERIVATIVE; KW 7158; LACTONE DERIVATIVE; LINOPIRDINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NIFEDIPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL STIMULATING AGENT; PYRAZOLONE DERIVATIVE; RETIGABINE; SULFONYLUREA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLADDER CONTRACTION; CLINICAL TRIAL; DETRUSOR MUSCLE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HYPERPOLARIZATION; NONHUMAN; OVERACTIVE BLADDER; POTASSIUM CURRENT; REVIEW; STRUCTURE ACTIVITY RELATION; URGE INCONTINENCE; XEROSTOMIA;

EID: 33646709872     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.5.573     Document Type: Review

References (57)

1. VELLA M, CARDOZO L: New developments in the management of urinary incontinence. Minerva Ginecologica (2005) 57(5):485-500.
2. ANDERSSON KE: Detrusor contraction - focus on muscarinic receptors. Scand. J. Urol. Nephrol. Suppl. (2004) (215):54-57.
3. ANDERSSON KE, WEIN AJ: Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol. Rev. (2004) 56(4):581-631.
4. CHESS-WILLIAM R: Potential therapeutic targets for the treatment of detrusor overactivity. Expert Opin. Ther. Targets. (2004) 8(2):95-106.
5. BURGARD EC, FRASER MO, KARICHETI V, RICCA DJ, THOR KB: New pharmacological treatments for urinary incontinence and overactive bladder. Curr. Opin. Investig. Drugs (2005) 6(1):81-89.
6. DMOCHOWSKI R: Improving the tolerability of anticholinergic agents in the treatment of overactive bladder. Drug Saf. (2005) 28(7):583-600.
7. BUTERA JA, ARGENTIERI TM: Recent approaches to the treatment of urinary incontinence: a survey of patent activity from 1995 to 1998. Expert Opin. Ther. Patents (1998) 8(8):1017-1035.
8. COPALAKRISHNAN M, SHIEH CC: Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Expert Opin. Ther. Targets. (2004) 8(5):437-458.
9. 3H-P1075 binding in bladder smooth muscle. Pharmacology (1995) 50:388-397.
10. WOJDAN A, FREEDEN C, WOODS M et al.: Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat. J. Pharmacol. Exp. Ther. (1999) 289:1410-1418.
11. FRYER RM, PREUSSER LC, CALZADILLA SV et al.: (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5, 6,7,9-hexahydrothieno[3,2-b]quinolin-8 (4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J. Cardiovasc. Pharmacol. (2004) 44(2):137-147.
12. SHYNG S, NICHOLS CG: Octameric stoichiometry of the KATP channel complex. J. Gen. Physiol. (1997) 110(6):655-664.
13. ATP) expressed in guinea pig bladder smooth muscle cells. J. Pharmacol. Exp. Ther. (1999) 289:551-558.
14. ATP channels containing SUR2B splice variants expressed in L-cells. Eur. J. Pharmacol. (2004) 483(2-3):195-205.
15. ATP channel activator. J. Med. Chem. (1997) 15:220-231.
16. ATP channel opener that selectively inbibits spontaneous bladder contractions. J. Med. Chem. (2004) 47:3163-3179.
17. ATP openers that potently inhibit bladder contractions in vitro. J. Med. Chem. (2004) 47:3180-3192.
18. ALTENBACH RJ, KONSTANTINOS A, DRIZIN I, CARROLL WA: 5-Amino-2H-pyran-3(6H)-one, a convenient intermediate in the synthesis of pyran containing 1,4-dihydropyridines. Synth. Comm. (2004) 34(4):557-565.
19. ATP channel openers (KCOs). Bioorg. Med. Chem. Lett. (2002) 12(11):1481-1484.
20. BAARNHIELM C, SKANBERG I, BORG KO: Cytochrome P450-dependent oxidation of felodipine-a 1,4-dihydropyridine-to the corresponding pyridine. Xenobiotica (1984) 14:719-726.
21. ATP channel openers. Bioorg. Med. Chem. (2004) 12:1895-1904.
22. BUTERA JA, ANTANE MM, ANTANE SA et al.: Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. I. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity. J. Med. Chem. (2000) 43:1187-1202.
23. GILBERT AM, ANTANE MM, ARGENTIERI TM et al.: Design and SAR of novel potassium channel openers targeted for urge urinary incontinence II. Selective and potent benzylamino cyclobutenediones. J. Med. Chem. (2000) 43:1203-1214.
24. BUTERA JA, ARGENTIERI TM: KCO-616 - Potassium channel opener. Treatment for urge urinary incontinence. Drugs Fut. (2000) 25(3):239-245.
25. MALMGREN A, ANDERSSON KE, SJOGREN C, ANDERSSON PO: Effects of pinacidil and cromakalim (BRL 34915) on bladder function in rats with detrusor instability. J. Urol. (1989) 142:1134-1138.
26. + channel opener, A-151892. Br. J. Pharmacol. (2004) 143:81-90.
27. ATP channel openers. Bioorg. Med. Chem. Lett. (2003) 13:1741-1744.
28. YOSHIMURA N, DE GROAT WC: Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J. Neurosci. (1999) 19(11):4644-4653.
29. HOLMQVIST MH, CAO J, HERNANDEZ-PINEDA R et al.: Elimination of fast inactivation in Kv4 A-type potassium channels by an auxiliary subunit domain. Proc. Natl. Acad. Sci. USA (2002) 99(2):1035-1040.
30. + currents in neurons of dorsal root ganglion of the adult rat. J. Pharmacol. Exp. Ther. (2004) 310(1):159-168.
31. LU S-H, YAMAGATA T, ATSUKI K et al.: Effects of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats. Brian Res. (2002) 946:72-78.
32. BURGARD EC, FRASER MO, KARICHETI V, RICCA DJ, THOR KB: New pharmacological treatments for urinary incontinence and overactive bladder. Curr. Opin. Investig. Drugs (2005) 6(1):81-89.
33. SHELDON JH, DAVIS A, NORTON NW et al.: Evidence for KCNQ gene expression and M-current activity in rat and human urinary bladder smooth muscle. ASPET-Ray Fuller Symposium on 'Lower urinary tract disorders: Physiology, pharmacology and therapeutic approaches' (6-7 July 2002).
34. + channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. (2000) 23:393-398.
35. ZACZEK R, CHORVAT RJ, SAYE JA et al.: Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9 (10H)-anthracenone: comparison to linopirdine. J. Pharmacol. Exp. Ther. (1998) 285:724-730.
36. + channel (KCNQ) opener retigabine in freely moving, conscious rats. J. Urol. (2004) 172(5, Pt.1):2054-2058.
37. + channels in neuronal cells. Eur. J. Pharmacol. (1997) 336(2-3):243-249.
38. RUNDFELDT C, NETZER R: The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. (2002) 82(1-2):73-76.
39. + channel modulators on detrusor and portal vein strips from guinea pigs. Pharmacology (1992) 45(4):216-230.
40. ZHANG XF, GOPALAKRISHNAN M, SHIEH CC: Modulation of action potential firing by iberiotoxin and NS1619 in rat dorsal root ganglion neurons. Neuroscience. (2003) 122(4):1003-1011.
41. MCMANUS OB, HELMS LM, PALLANCK L, GANETZKY B, SWANSON R, LEONARD RJ: Functional role of the beta subunit of high conductance calcium-activated potassium channels. Neuron. (1995) 14(3):645-650.
42. 2+-activated potassium channels by retaining the gating in the bursting states. J. Gen. Physiol. (1999) 113(3):425-440.
43. 2+ sensitivity. J. Gen. Physiol. (2000) 116(3):411-432.
44. + channel regulates contractile activity of mouse urinary bladder smooth muscle. J. Physiol. (2001) 537(Pt.2):443-452.
45. Ca and inhibition of calcium currents. J. Pharmacol. Exp. Therap. (1997) 283(3):1193-1200.
46. FUJII K, FOSTER CD, BRADING AF, PAREKH AB: Potassium channel blockers and the effects of cromakalim on the smooth muscle of the guinea-pig bladder. Br. J. Pharmacol. (1990) 99(4):779-785.
47. HERRERA GM, HEPPNER TJ, NELSON MT: Regulation of urinary bladder smooth muscle contractions by ryanodine receptors and BK and SK channels. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279(1):R60-R68.
48. HERRERA GM, POZO MJ, ZVARA P et al.: Urinary bladder instability induced by selective suppression of the murine small conductance calcium-activated potassium (SK3) channel. J. Physiol. (2003) 551(Pt.3):893-903.
49. ISHII TM, SILVIA C, HIRSCHBERG B, BOND CT, ADELMAN JP, MAYLIE J: A human intermediate conductance calcium-activated potassium channel. Proc. Natl. Acad. Sci. USA (1997) 94(21):11651-11656.
50. + channels in mouse urinary bladder smooth muscle cells. Japn. J. Pharmacol. (2000) 84(1):97-100.
51. BUTERA JA, ANTANE SA, HIRTH B et al.: Synthesis and potassium channel opening activity of substituted 10H-benzo[4,5]furo[3,2-b]indole- and 5,10-dihydro-indeno[1,2-b]indole-1-carboxylic acids. Bioorg. Med. Chem. Lett. (2001) 11:2093-2097.
52. BUTERA JA, JENKINS DJ, LENNOX JR et al.: Synthesis and bladder smooth muscle relaxing properties of 3-amino-4 aryl-(and aralkyl-)cyclobut-3-ene-1,2-diones. Bioorg. Med. Chem. Lett. (2005) 15:2495-2501.
53. WESOLOWSKI SS, JORGENSEN WL: Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response. Bioorg. Med. Chem. Lett. (2002) 12:267-270.
54. LESSIGIARSKA I, NANKOV A, BOCHEVA A, PAJEVA I, BIJEV A: 3D-QSAR and preliminary evaluation of anti-inflammatory activity of series of N-pyrrolylcarboxylic acids. Farmaco (2005) 60:209-218.
55. + channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles. Bioorg. Med. Chem. Lett. (2005) 13:2003-2007.
56. FOSTER CD, SPEAKMAN MJ, FUJII K, BRADING AF: The effects of cromakalim on the detrusor muscle of human and pig urinary bladder. Br. J. Urol. (1989) 63(3):284-294.
57. + channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. (2000) 23:393-398.